|Bid||0.00 x 1000|
|Ask||0.00 x 1300|
|Day's Range||144.47 - 150.54|
|52 Week Range||95.21 - 165.87|
|Beta (3Y Monthly)||1.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||209.95|
Gene therapy developers might steal all of the headlines, but manufacturing is likely to be the more lucrative investing opportunity -- for both companies and investors.
Sarepta Therapeutics, Inc. (SRPT) got a major boost in June after Pfizer, Inc. (PFE) presented data on its new Duchenne Muscular Dystrophy (DMD) gene therapy drug at the annual Parent Project Muscular Dystrophy (PPMD) conference. Pfizer’s drug left two patients in the hospital after they experienced severe side effects. Some analysts and financial bloggers believe that these results have SRPT perfectly positioned for sustainable long-term growth. So which stock should investors pick? Sarepta Has the Superior Treatment Sarepta is one of the leading commercial-stage biopharmaceutical companies, specializing in the treatment of rare diseases including DMD. DMD is a genetic disorder primarily affecting boys that causes progressive muscle degeneration and weakness. The company’s data looked stronger than PFE’s not only in terms of safety but also with respect to the level of transparency. Sarepta released Western Blot data showing that its treatment meets the accepted standards for dystrophin quantification, the only measure that’s present in every study. Pfizer on the other hand left this information out. SRPT’s other DMD treatment, Exondys 51, is already on the market and is the only DMD drug of its kind that’s commercially approved. Annual sales for the treatment totaled $301 million, up 95% from last year. As the drug doesn’t have any competition, it’s likely that sales will only continue to grow. This drug alone is expected to generate $400 million in revenues for 2019. The FDA is expected to approve SRPT’s new golodirsen drug for a different subgroup of patients with DMD on August 19. Not to mention the company acquired five new gene therapy candidates for $165 million in February. One of these therapies has already shown promising results for the treatment of Limb-Girdle Muscular Dystrophy. Pfizer Has Been Falling Behind Pfizer was attempting to break into the DMD treatment space, but the findings presented at the PPMD conference were disappointing. In a six-patient study, two different dosages of the gene therapy were given to boys between the ages of 6 to 12 years old. Side effects from the drug put two out of the six boys in the hospital. Experts also said that all measures of expression looked worse than SRPT’s and generally unsafe. This is not the first time the pharmaceutical giant has failed to produce an effective DMD treatment. In August 2018, Pfizer dropped its domagrozumab (PF-06252616) DMD candidate based on poor safety and efficacy test results.The company’s loss of exclusivity for its pain medication, Lyrica, as well as the controversy surrounding drug pricing isn’t helping the situation. Share prices are down 3% year-to-date, with analysts expecting -5% earnings growth for the current quarter. What are the Analysts Saying?With strong results from existing treatments and the possibility of new treatments becoming available, the future is looking bright for SRPT. Morgan Stanley analyst, Matthew Harrison, agrees with that sentiment. On July 9, he reiterated his Buy rating and raised his price target from $165 to $220. “Sarepta's DMD gene therapy is positioned to be the first to market, taking a majority share of the ~$20B prevalent population in the US and expanding internationally with a significant lead. Based on our proprietary analysis we believe investors underappreciate the magnitude of Sarepta’s best-in-class efficacy compared to Pfizer,” he said.On July 1, another top analyst, Brian Abrahams, maintained his Buy rating while increasing the price target from $188 to $220. “Based on our analysis of PFE's initial DMD gene therapy results - incorporating the on-site sentiment from KOLs and patients - we see SRPT as the clear leader in this space and are increasing our out-year DMD share/penetration estimates,” he said. The Takeaway The results are in, and SRPT is the clear winner. The stock boasts a ‘Strong Buy’ analyst consensus, with 12 buy ratings vs just 1 hold over the last three months. The average price target is $215, suggesting 40% upside potential.Click Here to see the full list of SRPT Analyst RatingsAnalysts are not as optimistic about Pfizer. The stock has a ‘Moderate Buy’ analyst consensus and $47 price target, suggesting 9% upside. SRPT & PFE Performance Comparison Details
During Thursday night's Lightning Round one caller inquired about Sarepta Therapeutics Inc. : "I think they're brilliant. In the daily bar chart of SRPT, below, we can see an "interesting pattern." SRPT has been in a long sideways consolidation pattern, but look closer. Draw an imaginary line across $120 or $110 -- notice all the dips into that area?
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.
Pfizer disclosed data for its Duchenne muscular dystrophy that appeared to be inferior to Sarepta’s, sending the latter’s shares surging on Friday.
Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.
Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.
Sarepta Therapeutics stock rocketed in high volume Friday after Pfizer said its gene therapy test is on pause following serious side effects in two boys with Duchenne muscular dystrophy.
Baird analyst Brian Skorney said in a note that "Pfizer fell way short on both safety and efficacy" for a gene therapy drug for a genetic degenerative disorder affecting 1 in 3,500 to 5,000 men. Sarepta is making a competing drug, called Exondys 51, and has been gaining market share in the space for such types of drugs, according to RBC Capital Markets analysts. Pfizer mentioned what some of the drug's safety concerns were in a press release Friday.
(Bloomberg) -- Wall Street analysts are more bullish on Sarepta Therapeutics Inc. and its market-leading gene therapy for Duchenne muscular dystrophy after Pfizer Inc.’s early results for a competing medicine showed largely uninspiring effectiveness and safety concerns.RBC analyst Brian Abrahams advised clients to continue buying Sarepta shares amid a 20% rally as the Pfizer data remove a competitive overhang and further established Sarepta’s “significant lead in the space.” Another Sarepta bull is Baird’s Brian Skorney, who said “Pfizer fell way short on both safety and efficacy” and piled on praise for the safety of Sarepta’s therapy.Shares of the Cambridge, Massachusetts-based drugmaker surged as much as 20% to $155.75, the most since a presentation of its initial data a year ago, to trade near the highest level since October. Pfizer stock erased initial losses to trade higher with the broader market as Solid Biosciences Inc. rose to touch the highest level in a month.Here’s a roundup of what analysts are saying:Baird, Brian Skorney“We believe Sarepta’s position in DMD is even stronger coming out of PPMD. Pfizer fell way short on both safety and efficacy. All measures of expression looked worse, in our view.”Pfizer data didn’t look safe with bad side effects, and “even more concerning, was a hospitalization due to complement activation and acute kidney injury.”While it’s not over for Pfizer with a pivotal trial expected next year, “we think it should be.”Rates Sarepta a Fresh Pick outperform with a $202 price target.RBC, Brian Abrahams“This represented a best-case scenario” for Sarepta, with a significant safety setback for Pfizer helping to enhance Sarepta’s lead time and potentially make it challenging for Pfizer to recruit additional patients.“With this competitive overhang past and SRPT’s likely significant lead in the space established, we would be buyers into strength, as we expect the focus to expand to better recognition of the potential not only for microdystrophin/DMD but also SRPT’s other gene therapies.”Pfizer’s therapy looked active, though the choice of assay makes comparisons to Sarepta challenging with safety issues that are notable. Data had a meaningful number of side effects with “notably a high rate of nausea, vomiting, anorexia and fatigue,” with one patient going into acute renal failure.Rates Sarepta outperform with a $188 price target.William Blair, Tim LugoSarepta is the “clear leader in DMD with no close No. 2 after Prizer results disappoint” with Sarepta having best-in-class efficacy data.“We see this as validation of the microdystrophin gene therapy class approach for treatment of DMD, rebutting the bear thesis that microdystrophin expression is not a functional surrogate of full length dystrophin.”Rates Sarepta outperform.Cantor Fitzgerald, Louise Chen“While we view the early secondary and exploratory data positively, we think safety will continue to be a focus as Pfizer progresses to its Phase 3 trial.”There will be upside for Pfizer if it’s able to commercialize the drug, though Wall Street expectations were modest going into the data. Thinks Pfizer’s plans to move into a Phase 3 program is positive though investors will want more color on manufacturing and safety.Rates Pfizer overweight with price target at $53.To contact the reporter on this story: Bailey Lipschultz in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Lisa WolfsonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Sarepta reported promising data from its study last year and is in a race with Pfizer and Solid Biosciences Inc to first market a gene therapy for the genetic degenerative disorder that affects one in 3,500 to 5,000 males. Shares of Pfizer were marginally up in midday trading, while Sarepta shares were up 15% and Solid Biosciences was up about 10%.
Pfizer Inc on Friday presented promising results from a tiny early study of its experimental gene therapy for a rare muscle disease, but two of the six patients in the trial experienced side effects that landed them in the hospital. Duchenne muscular dystrophy (DMD) is a genetic degenerative disease that affects one in 3,500 to 5,000 males. People with the condition lack the protein dystrophin needed to keep muscle cells intact.
Investors need to pay close attention to Sarepta Therapeutics (SRPT) stock based on the movements in the options market lately.
Sarepta Therapeutics will face a "whale" of an overhang Friday when Dow Jones stock Pfizer unveils the results of its gene therapy in Duchenne muscular dystrophy, an analyst said Monday.
Sarepta Therapeutics Inc NASDAQ/NGS:SRPTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding SRPT are favorable, with net inflows of $2.74 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. But when you hold the...
The field of biotechs developing treatments for Duchenne muscular dystrophy became more crowded this week, with biotech startup Dyne setting its sights on the muscle-wasting rare disease.
Is Sarepta Therapeutics Inc (NASDAQ:SRPT) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]
Vertex Pharmaceuticals recently doubled down on its gene editing collaboration with CRISPR Therapeutics, but it's miles behind an arguably simpler solution.